---
title: CD-NP (Cenderitide) Therapy for the Preservation of Left Ventricular Function
nct_id: NCT02071602
overall_status: COMPLETED
phase: PHASE1
sponsor: Mayo Clinic
study_type: INTERVENTIONAL
primary_condition: ST Elevation (STEMI) Myocardial Infarction of Anterior Wall
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT02071602.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT02071602"
ct_last_update_post_date: 2021-03-10
last_seen_at: "2026-05-12T07:10:56.285Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# CD-NP (Cenderitide) Therapy for the Preservation of Left Ventricular Function

**Official Title:** CD-NP (Cenderitide) Therapy for the Preservation of Left Ventricular Function Post Anterior Myocardial Infarction - Pilot Study

**NCT ID:** [NCT02071602](https://clinicaltrials.gov/study/NCT02071602)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE1
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 30
- **Lead Sponsor:** Mayo Clinic
- **Conditions:** ST Elevation (STEMI) Myocardial Infarction of Anterior Wall
- **Start Date:** 2013-10
- **Completion Date:** 2018-11
- **CT.gov Last Update:** 2021-03-10

## Brief Summary

The primary endpoint is to assess the safety and tolerability of Cenderitide (CD-NP) with the incidence of symptomatic hypotension being one of the key safety variables.

## Detailed Description

This is a "proof of concept", randomized, double-blind, placebo controlled study. The study population will include 60 patients admitted with a first time ST elevation anterior STEMI as diagnosed by the following criteria: a) Significant chest discomfort and /or shortness of breath; b) ST segment elevation (1.5 mV total) in two or more adjacent anterior precordial leads; c) Successful reperfusion therapy (\>TIMI grade 2 flow) either with thrombolytics or PTCA within 24 hours of onset of symptoms as documented by coronary angiography; and d) No previous history of an anterior AMI or previous ECG suggesting an old anterior AMI.

Patients will be randomized to one of two doses of CD-NP (5 ng/kg/min and 10 ng/kg/min) or placebo continuous infusion for up to 72 hours in a 1:1:1 manner. All patients will receive other standard medical therapies as determined appropriate by the physician and in accordance to the ACC/AHA guidelines

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Significant chest discomfort and /or shortness of breath
* ST segment elevation (1.5 mV total) in two or more adjacent anterior precordial leads
* Successful reperfusion therapy (\>TIMI grade 2 flow) either with thrombolytics or any mechanical forms of revascularization, including stent, PTCA, thrombectomy, etc. within 24 hours of onset of symptoms as documented by coronary angiography
* No previously known history of AMI (prior to current cardiac event) or no previous ECG (prior to current cardiac event) suggesting an old AMI (Q wave on presenting ECG is not an exclusion)..

Exclusion Criteria:(Assessed at the time of enrollment unless otherwise stated)

* Cardiogenic shock, acute heart failure or hypotension (Systolic BP \< 90 mmHg)
* Previous known decreased EF \< 40%
* Atrial Fibrillation
* Persistent signs and symptoms of Post MI ischemia
* Requirement of pressors for maintenance of blood pressure.
* Intra-aortic blood pump use
* Significant (moderate-severe) valvular stenosis, hypertrophic, restrictive or obstructive cardiomyopathy, constrictive pericarditis, primary pulmonary hypertension.
* Severe congenital heart diseases
* Sustained ventricular tachycardia or ventricular fibrillation
* Second or third degree heart block without a permanent cardiac pacemaker
* Stroke within 3 months or other evidence of significantly compromised CNS perfusion
* Total bilirubin of \> 2.5 mg/dL or other liver enzymes \>2.5 times the upper limit of normal if available clinically and measured within the last 7 days
* Patients with calculated GFR \<30 ml by MDRD equation or those with acute kidney injury as defined by an increase of plasma creatinine of 0.5 mg/dL from a plasma creatinine measured within the last 7 days
* Serum sodium of \< 125 mEq/dL or \> 160 mEq/dL if available clinically and measured within the last 7 days
* Serum potassium of \< 3.0 mEq/dL or \> 5.8 mEq/dL if available clinically and measured within the last 7 days
* Hemoglobin \< 8.5 gm/dl if available clinically and measured within the last 7 days
* Other acute or chronic medical conditions or laboratory abnormality which may increase the risks associated with study participation or may interfere with interpretation of the data
* Received an investigational drug within 1 month prior to dosing
* Female subject who is pregnant or breastfeeding
* In the opinion of the investigator, is unlikely to comply with the study protocol or is unsuitable for any reasons
```

## Arms

- **Placebo** (PLACEBO_COMPARATOR) — Placebo infused for up to 72 hours IV
- **CD-NP 5 ng/kg/min** (ACTIVE_COMPARATOR) — CD-NP 5 ng/kg/min infused for up to 72 hours IV
- **CD-NP 10 ng/kg/min** (PLACEBO_COMPARATOR) — CD-NP 10 ng/kg/min infused for up to 72 hours IV

## Interventions

- **CD-NP** (DRUG) — Randomized 1:1:1

## Primary Outcomes

- **Number of subjects with symptomatic hypotension** _(time frame: baseline to 30 days)_

## Secondary Outcomes

- **Comparison of LV function improvement between placebo vs. CD-NP groups** _(time frame: baseline to 30 days)_
- **Exploratory analyses of Major Adverse Cardiovascular Events (MACE)** _(time frame: 30 days)_

## Locations (1)

- Mayo Clinic in Rochester, Rochester, Minnesota, United States

## Recent Field Changes (last 30 days)

- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.mayo clinic in rochester|rochester|minnesota|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT02071602.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT02071602*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*